Keeping Track: A Diverse Array Of Approvals, A CRL For Evolus' Botox Competitor, And Coherus Refiles Neulasta Biosimilar

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

Here's your product review news in brief from the US last week: Another fresh wave of approvals came out of FDA, most notably the agency's backing of US WorldMeds LLCLucemyra (lofexidine) as the first non-opioid indicated for the management of opioid withdrawal symptoms.

Also joining the novel product front was Amgen Inc. and Novartis AG's preventative migraine treatment Aimovig (erenumab-aooe), the first of the three calcitonin gene-related peptide receptor (CGRP) antagonists...

More from Product Reviews

More from Pink Sheet